Verona Pharmaceuticals, a clinical stage biopharmaceutical company headquartered in the UK, announced the completion of enrollment to its ENHANCE-1 trials to evaluate nebulized ensifentrine for the management of COPD. The scientists involved in the trial said that the fully-enrolled 48-week subset of the ENHANCE-1 trial was critical in delivering top-line data. The company said that the data from ENHANCE-1 trials is expected around the end of 2022 and from ENHANCE-2 trials are expected in the third quarter of 2022. Verona Pharma had previously said that ensidentrine is a first-in-class product candidate that combines bronchodilator and anti-inflammatory activities in one compound providing relief to COPD patients.